EU6 Stock Chart & Stats
€0.61
>-€0.01(-0.97%)
At close: 4:00 PM EDT
€0.61
>-€0.01(-0.97%)
Day’s Range― - ―
52-Week Range€0.19 - €1.22
Previous CloseN/A
Volume0.00
Average Volume (3M)248.00
Market Cap
€9.97M
Enterprise Value€47.81
Total Cash (Recent Filing)€5.60M
Total Debt (Recent Filing)€4.36M
Price to Earnings (P/E)―
Beta1.11
Next Earnings
Nov 12, 2026EPS Estimate
-0.1Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.64
Shares Outstanding55,971,336
10 Day Avg. Volume0
30 Day Avg. Volume248
Financial Highlights & Ratios
PEG Ratio0.04
Price to Book (P/B)3.86
Price to Sales (P/S)0.00
P/FCF Ratio>-0.01
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€6.04Price Target Upside890.64% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.46
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Strategic Focus On PDS0301Prioritizing PDS0301 concentrates limited capital on the company’s strongest reported clinical opportunity. The response and survival data, plus treatment across multiple solid-tumor settings, could support a focused development and partnering strategy.
Strengthened IP And Manufacturing ReadinessLong-dated patent protection can preserve commercial differentiation if clinical development succeeds, while an established manufacturing process and scale-up reduce execution risk and provide a clearer path toward a potential BLA.
Lower Operating Cost BaseReduced operating expenses and a smaller quarterly loss show progress toward capital discipline. If maintained without impairing development, a leaner cost base could extend resources available for the prioritized pipeline and reduce future funding needs.
Bears Say
Pre-revenue And Persistent LossesWith no demonstrated commercial revenue, PDSB remains dependent on clinical success, partnerships or financing to fund operations. Persistent losses limit internal capital generation and make the business highly sensitive to development setbacks.
Stressed Balance SheetNegative equity and elevated debt materially weaken financial flexibility and increase solvency and refinancing risk. This balance-sheet pressure can constrain investment in the pipeline and raise the cost or dilution associated with future capital.
Limited Liquidity And Financing DependenceThe sharply reduced cash balance underscores funding pressure while late-stage development continues. Expanded share authorization increases financing flexibility but also creates meaningful dilution risk, reinforcing dependence on external capital or partnerships.
PDS Biotechnology News
EU6 FAQ
What was Pds Biotechnology’s price range in the past 12 months?
Pds Biotechnology lowest stock price was €0.19 and its highest was €1.22 in the past 12 months.
What is Pds Biotechnology’s market cap?
Pds Biotechnology’s market cap is €9.97M.
When is Pds Biotechnology’s upcoming earnings report date?
Pds Biotechnology’s upcoming earnings report date is Nov 12, 2026 which is in 83 days.
How were Pds Biotechnology’s earnings last quarter?
Pds Biotechnology released its earnings results on Aug 13, 2026. The company reported -€0.155 earnings per share for the quarter, missing the consensus estimate of -€0.112 by -€0.043.
Is Pds Biotechnology overvalued?
According to Wall Street analysts Pds Biotechnology’s price is currently Undervalued.
Does Pds Biotechnology pay dividends?
Pds Biotechnology does not currently pay dividends.
What is Pds Biotechnology’s EPS estimate?
Pds Biotechnology’s EPS estimate is -0.1.
How many shares outstanding does Pds Biotechnology have?
Pds Biotechnology has 55,971,336 shares outstanding.
What happened to Pds Biotechnology’s price movement after its last earnings report?
Pds Biotechnology reported an EPS of -€0.155 in its last earnings report, missing expectations of -€0.112. Following the earnings report the stock price went down -4.63%.
Which hedge fund is a major shareholder of Pds Biotechnology?
Currently, no hedge funds are holding shares in DE:EU6
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Pds Biotechnology
PDS Biotechnology Corporation is a clinical-stage biopharmaceutical firm dedicated to advancing innovative, multi-functional immunotherapies to combat cancer. Its primary drug candidate, PDS0101 (HPV16), is currently undergoing Phase II clinical trials, positioned as an initial treatment option for recurrent or metastatic head and neck cancer, human papillomavirus (HPV)-associated malignancies, and cervical cancer. The company's developmental pipeline further includes several preclinical product candidates. These comprise PDS0102, utilizing T-cell receptor gamma alternate reading frame protein (TARP) for prostate and breast cancers; PDS0103 (MUC-1) targeting ovarian, colorectal, lung, and breast cancers; and PDS0104, which incorporates Tyrosinase-related protein 2 for the treatment of melanoma. Beyond oncology, PDS Biotechnology is also engaged in developing treatments for infectious diseases, with candidates such as PDS0201 for tuberculosis, PDS0202 as an investigational influenza vaccine, and PDS0203, a vaccine aimed at preventing COVID-19. The company has established strategic partnerships and licensing agreements with notable entities including the National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. PDS Biotechnology Corporation was founded in 2005 and is headquartered in Florham Park, New Jersey.
EU6 Earnings Call
Q1 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call conveyed meaningful clinical and intellectual property progress: a strategic protocol amendment for VERSATILE-003 that reduces patient count (~28.6%) and time to an interim readout, peer-reviewed and encouraging clinical data for PDS01ADC, strengthened IP extending PDS0101 protection into the 2040s, and established manufacturing processes. Financially, operating expenses and net loss improved year-over-year. Key risks include a relatively modest cash balance ($21.7M), continued unprofitability with rising interest expense, the need for OS data for full approval and additional confirmatory trials, and competition in the HPV16 head and neck space. On balance, the operational and clinical positives outweigh the near-term financial and development risks.View all DE:EU6 earnings summariesEU6 Stock 12 Month Forecast
Average Price Target
€6.04
▲(890.64% Upside)